MSLN and neoplasm: In a phase III clinical trial (169) on patients with advanced pancreatic cancer that expressed glypican-1 or mesothelin, anti-mesothelin-7*19 CAR-T therapy resulted in near complete tumor eradication at 240 days after intravenous infusion.